Article Text

Download PDFPDF

Associations of Fc gamma receptor (FcgR2a, FcgR3a and FcgR2c) genotype with outcome in metastatic renal cell carcinoma (mRCC) patients receiving high dose interleukin 2 (HD-IL2)
  1. Amy K Erbe1,
  2. Wei Wang1,
  3. Kyung Mann Kim2,
  4. Laskeesha Carmichael2,
  5. MIkayla Gallendberger1,
  6. Dustin Hess1,
  7. Eneida A Mendonca3,
  8. Yiqiang Song2,
  9. Jacquelyn A Hank1,
  10. Su-Chun Chen4,
  11. Sabina Signoretti5,
  12. Michael B Atkins6,
  13. Alexander Carlson7,
  14. James Mier8,
  15. David Panka7,
  16. David F McDermott8 and
  17. Paul M Sondel9
  1. Aff1 grid.14003.360000000099041312Department of Human OncologyUniversity of Wisconsin-Madison Madison WI USA
  2. Aff2 grid.14003.360000000099041312Department of Biostatistics and Medical InformaticsUniversity of Wisconsin-Madison Madison WI USA
  3. Aff3 grid.14003.360000000099041312Department of Biostatistics and Medical Informatics, Department of PediatricsUniversity of Wisconsin-Madison Madison WI USA
  4. Aff4 grid.65499.370000000121069910Department of BiostatisticsDana Farber Cancer Institute Boston MA USA
  5. Aff5 grid.62560.370000000403788294Department of PathologyBrigham and Women's Hospital Boston MA USA
  6. Aff6 grid.213910.80000000119551644The Cytokine Working Group; Department of MedicineGeorgetown-Lombardi Comprehensive Cancer Center Washington DC USA
  7. Aff7 grid.239395.70000000090118547Division of Hematology/OncologyBeth Israel Deaconess Medical Center Boston MA USA
  8. Aff8 grid.239395.70000000090118547The Cytokine Working Group; Division of Hematology/OncologyBeth Israel Deaconess Medical Center Boston MA USA
  9. Aff9 grid.14003.360000000099041312Department of Human Oncology, Department of PediatricsUniversity of Wisconsin-Madison Madison WI USA

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts

HD-IL2 was given to patients with mRCC in a prospective trial ( ID: NCT00554515) that demonstrated an overall response rate of 25%. To identify predictors of response, we genotyped patients for single nucleotide polymorphisms (SNPs) in FcgR genes: FcgR2a, FcgR3a, and FcgR2c. These FcgRs are variably expressed on immune cells, and bind to the IgG portion of antibodies, triggering activation.

FcgR2a [SNP = histidine/arginine (H/R); expressed on neutrophils, monocytes-macrophages and antigen-presenting cells (APCs)] and FcgR3a [SNP = valine/phenylalanine (V/F); expressed on NK cells and some APCs] impact patient response to immunotherapy [mainly monoclonal antibody-based (mAb) therapies] in several malignancies, as both FcgR2a-H and FcgR3a-V have higher antibody binding affinity than FcgR2a-R or FcgR3a-F, respectively. FcgR2c, also expressed on NK cells, has a SNP that regulates its expression [C nucleotide = expression; T nucleotide = non-expression (C/T)]. About 20-40% of individuals express FcgR2c; little is known about the role of FcgR2c expression in cytokine-based immunotherapy.

We found associations of FcgR genotypes with patient response to HD-IL2. Dual combination analyses of FcgR3a with FcgR2a genotypes revealed significantly improved %Tumor Shrinkage in patients with either FcgR3a-VV and/or FcgR2a-HH (n=34) as compared to those patients genotyped as FcgR3a-VF or FF with FcgR2a-HR or RR (n=70) (p=0.047). For analyses including both FcgR3a and FcgR2c genotypes, significantly improved OS was seen in those with ≥2 alleles of either FcgR3a-V and/or FcgR2c-C (n=27) vs. those with < 2 alleles of either FcgR3a-V and/or FcgR2c-C (n=79) (p=0.013). We further considered combinations that included the genotypes of all 3 genes; we identified 42 patients with “favorable” genotypes and 64 with “unfavorable”. We saw significant improvement in the %Tumor shrinkage (p = 0.033) and a trend for improvement in OS (p = 0.071) in the “favorable genotype” group.

As reported previously by others, some cancer patients make endogenous anti-tumor Ab. The association of these “favorable” FcgR genotypes with outcome suggests there may be a beneficial interaction of “favorable” FcR genotypes with endogenous anti-tumor Ab. Favorable FcgRs may support the induction of in vivo antibody-dependent cell-mediated cytotoxicity (ADCC) or antibody-dependent cellular phagocytosis (ADCP). In addition, ADCP by APC with a favorable pattern of FcgRs, may be playing a role in enhancing induction of effective adaptive immunity, via augmented antigen presentation. Further analyses are needed to validate these exploratory findings and clarify the mechanisms by which these favorable FcgR genotypes are associated with improved outcome in these patients with mRCC treated with HD-IL2.